{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-050545","form_type":"8-K","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2024-12-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.295320+00:00","generated_at":"2026-05-29T04:58:44.752669+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Sangamo: Phase 3 hemophilia A gene therapy succeeds; share authorization suit resolved","bullets":["Phase 3 AFFINE trial met primary endpoint: mean ABRtotal reduced from 4.73 (prophylaxis) to 1.24 post infusion (p=0.004).","84% of participants (42/50) achieved FVIII activity >5% at Month 15; 88% had no treated bleeds.","Safety: no FVIII inhibitors, no treatment-related malignancies; ALT elevations manageable with corticosteroids.","Delaware Court validated share increase vote standard; Sangamo dismissed Section 205 application."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-050545","json":"https://secwatch.observer/filing/0001628280-24-050545.json","markdown":"https://secwatch.observer/filing/0001628280-24-050545.md","text":"https://secwatch.observer/filing/0001628280-24-050545.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000162828024050545/0001628280-24-050545-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000162828024050545/sgmo-20241209.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T04:58:44.752669+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}